Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm specializing in immuno-neurology, announced that Chief Business Officer Sabah Oney, Ph.D., will speak at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 11:00 a.m. ET. The event aims to discuss Alector's innovative approaches to treating neurodegenerative diseases by targeting immune dysfunction. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
Alector, a clinical-stage biotechnology company, announced positive preliminary results from the Phase 1b and Phase 2 studies of its investigational drug AL001 for treating frontotemporal dementia with a progranulin gene mutation (FTD-GRN). AL001 demonstrated general safety, restoring plasma progranulin levels to normal in all participants, with many showing decreased neurofilament light chain (NfL) levels. The pivotal Phase 3 study of AL001 commenced in July 2020, aiming to evaluate its efficacy in symptomatic and pre-symptomatic patients.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced management participation in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. ET. The live webcast can be accessed on Alector's Investors page, with a replay available for 30 days post-event. Alector's approach targets immune dysfunction in neurodegenerative diseases, specifically in frontotemporal dementia and Alzheimer's disease, aiming to repair genetic mutations affecting the brain's immune response.